- In March 2026, Johnson & Johnson announced a US$500 million R&D co-funding agreement with Royalty Pharma across 2026 and 2027 to advance JNJ-4804, a novel co-antibody therapy targeting both IL-23 and TNF pathways in autoimmune diseases.
- This collaboration gives Royalty Pharma exposure to an early-stage, dual-pathway autoimmune candidate that could meaningfully influence the mix and risk profile of its royalty portfolio.
- Next, we’ll examine how this substantial R&D co-funding commitment around JNJ-4804 may reshape Royalty Pharma’s investment narrative and pipeline exposure.
The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Royalty Pharma Investment Narrative Recap
To own Royalty Pharma, you need to believe in its ability to turn a diversified stream of biopharma royalties into steady, compounding cash flows while managing concentration and policy risk. The new US$500 million co-funding deal with Johnson & Johnson adds early-stage autoimmune exposure, but it does not change the fact that the biggest near term swing factor remains the Vertex Alyftrek royalty dispute, with competitive pressure in royalty deals still a key overhang.
Among recent developments, the 2026 guidance for portfolio receipts of US$3,275 million to US$3,425 million is most relevant here, because it frames how much room Royalty Pharma has to fund deals like JNJ-4804 while still supporting buybacks and dividends. The company’s willingness to increase the quarterly dividend to US$0.235 per share in early 2026 also underlines management’s confidence in cash generation as it layers new, earlier stage partnerships onto its existing royalty base.
Yet, against this opportunity, one risk that investors should be aware of is how rising competition for royalty assets could...
Read the full narrative on Royalty Pharma (it's free!)
Royalty Pharma’s narrative projects $4.0 billion revenue and $922.7 million earnings by 2028. This requires 20.0% yearly revenue growth and an earnings decrease of about $77 million from $1.0 billion today.
Uncover how Royalty Pharma's forecasts yield a $51.56 fair value, a 9% upside to its current price.
Exploring Other Perspectives
Some bullish analysts were already modeling around US$4.3 billion of revenue and roughly US$894 million of earnings by 2028, a far more optimistic path than consensus, so this J&J deal may either reinforce that upbeat view or prompt a rethink if concentration and competitive risks evolve differently than expected.
Explore 5 other fair value estimates on Royalty Pharma - why the stock might be worth just $46.00!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Royalty Pharma research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Royalty Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Royalty Pharma's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com